Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$1.4 million.

  • Vivos Therapeutics' Net Cash Flow fell 12380.17% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.7 million, marking a year-over-year decrease of 37848.75%. This contributed to the annual value of $4.6 million for FY2024, which is 34562.9% up from last year.
  • According to the latest figures from Q3 2025, Vivos Therapeutics' Net Cash Flow is -$1.4 million, which was down 12380.17% from -$9.4 million recorded in Q2 2025.
  • Vivos Therapeutics' Net Cash Flow's 5-year high stood at $20.1 million during Q2 2021, with a 5-year trough of -$9.4 million in Q2 2025.
  • Moreover, its 5-year median value for Net Cash Flow was -$3.1 million (2023), whereas its average is -$1.4 million.
  • Examining YoY changes over the last 5 years, Vivos Therapeutics' Net Cash Flow showed a top increase of 646117.0% in 2021 and a maximum decrease of 105471.91% in 2021.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Net Cash Flow stood at -$4.5 million in 2021, then grew by 28.95% to -$3.2 million in 2022, then skyrocketed by 120.53% to $657000.0 in 2023, then crashed by 101.67% to -$11000.0 in 2024, then plummeted by 12209.09% to -$1.4 million in 2025.
  • Its Net Cash Flow was -$1.4 million in Q3 2025, compared to -$9.4 million in Q2 2025 and -$3.9 million in Q1 2025.